Group One Trading’s NovoCure NVCR Stock Holding History

Group One Trading’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.22M	Sell	112,300 -4,300	-4%	-$53.7K	﹤0.01%	2520
2025 Q4	$1.51M	Sell	116,600 -57,500	-33%	-$738K	﹤0.01%	2521
2025 Q3	$2.25M	Buy	174,100 +43,300	+33%	+$579K	﹤0.01%	2195
2025 Q2	$2.33M	Buy	130,800 +1,300	+1%	+$22.7K	0.01%	1985
2025 Q1	$2.31M	Sell	129,500 -263,200	-67%	-$5.98M	0.01%	1698
2024 Q4	$11.7M	Buy	392,700 +135,800	+53%	+$2.87M	0.03%	613
2024 Q3	$4.02M	Buy	256,900 +3,200	+1%	+$58K	0.01%	1169
2024 Q2	$4.35M	Buy	253,700 +2,900	+1%	+$51K	0.02%	894
2024 Q1	$3.92M	Buy	250,800 +124,100	+98%	+$1.83M	0.02%	989
2023 Q4	$1.89M	Sell	126,700 -8,900	-7%	-$119K	0.01%	1919
2023 Q3	$2.19M	Sell	135,600 -50,500	-27%	-$1.46M	0.01%	1573
2023 Q2	$7.72M	Buy	186,100 +32,300	+21%	+$2.01M	0.02%	666
2023 Q1	$9.25M	Sell	153,800 -148,000	-49%	-$11.8M	0.03%	512
2022 Q4	$22.1M	Buy	301,800 +128,400	+74%	+$9.66M	0.05%	363
2022 Q3	$13.2M	Buy	173,400 +2,100	+1%	+$164K	0.03%	582
2022 Q2	$11.9M	Sell	171,300 -38,800	-18%	-$2.92M	0.02%	733
2022 Q1	$17.4M	Buy	210,100 +32,100	+18%	+$2.36M	0.02%	676
2021 Q4	$13.4M	Buy	178,000 +88,300	+98%	+$8.86M	0.01%	897
2021 Q3	$10.4M	Sell	89,700 -86,400	-49%	-$13.1M	0.01%	1036
2021 Q2	$39.1M	Sell	176,100 -19,700	-10%	-$3.83M	0.05%	335
2021 Q1	$25.9M	Buy	195,800 +12,200	+7%	+$1.93M	0.04%	423
2020 Q4	$31.8M	Buy	183,600 +19,800	+12%	+$2.71M	0.06%	294
2020 Q3	$18.2M	Buy	163,800 +72,000	+78%	+$5.76M	0.06%	300
2020 Q2	$5.44M	Sell	91,800 -74,200	-45%	-$4.88M	0.03%	755
2020 Q1	$11.2M	Buy	166,000 +134,000	+419%	+$10.6M	0.09%	226
2019 Q4	$2.7M	Sell	32,000 -49,900	-61%	-$4.03M	0.02%	1062
2019 Q3	$6.12M	Buy	81,900 +57,600	+237%	+$4.61M	0.05%	474
2019 Q2	$1.54M	Sell	24,300 -67,700	-74%	-$3.43M	0.01%	1291
2019 Q1	$4.43M	Buy	92,000 +71,700	+353%	+$3.45M	0.05%	486
2018 Q4	$680K	Sell	20,300 -4,200	-17%	-$154K	0.01%	1788
2018 Q3	$1.28M	Buy	24,500 +4,200	+21%	+$167K	0.01%	1496
2018 Q2	$635K	Sell	20,300 -31,300	-61%	-$871K	0.01%	2104
2018 Q1	$1.13M	Buy	51,600 +39,500	+326%	+$850K	0.01%	1433
2017 Q4	$244K	Sell	12,100 -6,600	-35%	-$127K	﹤0.01%	2804
2017 Q3	$371K	Sell	18,700 -132,300	-88%	-$2.6M	﹤0.01%	2314
2017 Q2	$2.61M	Buy	151,000 +9,300	+7%	+$120K	0.03%	798
2017 Q1	$1.15M	Buy	141,700 +104,200	+278%	+$752K	0.01%	1250
2016 Q4	$294K	Buy	37,500 +27,500	+275%	+$221K	﹤0.01%	2148
2016 Q3	$85K	Buy	10,000 +7,700	+335%	+$70.2K	﹤0.01%	3039
2016 Q2	$27K	Buy	2,300 +2,000	+667%	+$25K	﹤0.01%	3651
2016 Q1	$4K	Buy	+300	New	+$4.3K	﹤0.01%	4250

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Group One Trading's NVCR Position: Q1 2026 in Review

Group One Trading sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 22,597 shares — an estimated $282K sold.

Group One Trading first reported a position in NVCR in Q4 2015 and held it in 18 quarters. The position peaked at $3.71M in Q4 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Group One Trading reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
Group One Trading sold 22,597 NovoCure shares in Q1 2026, an estimated $282K.
Group One Trading first reported a position in NovoCure in Q4 2015 and held it in 18 quarters.
Group One Trading's NovoCure position peaked at $3.71M in Q4 2021.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.